Press releases

11.Oct 21

Scandion Oncology A/S: Postponement of extraordinary general meeting
We hereby announce that the planned extraordinary general meeting of Scandion...

04.Oct 21

Scandion Oncology A/S: Cancellation of extraordinary general meeting
We hereby announce cancellation of the planned extraordinary general meeting ...

21.Sep 21

Scandion Oncology A/S: Notice convening an Extraordinary General Meeting
We hereby convene an Extraordinary General Meeting of Scandion Oncology A/S (...

08.Sep 21

Scandion Oncology provides a clear path to market for SCO-101 at today’s Capital Markets Day
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced it...

07.Sep 21

Scandion Oncology strengthens its Clinical Advisory Board with three new members
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced th...

06.Sep 21

Scandion Oncology receives approval for initiating the CORIST part 2 trial
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced th...

02.Sep 21

Positive Results from the Scandion Oncology A/S and Alligator Bioscience AB Collaboration Further Supports Efficacy of SCO-101 in Combination Therapy
Copenhagen, Denmark, September 2, 2021 – Scandion Oncology (Nasdaq Stockholm:...

27.Aug 21

Scandion Oncology receives German trial approval for PANTAX Ib study
Scandion Oncology A/S today announced that the company has obtained approval ...

25.Aug 21

First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced th...

19.Aug 21

Scandion Oncology A/S announces its results for the first half year of 2021

Load more (100)